Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ghrelin Suppression by Sandostatin LAR® Depot (Octreotide Acetate for Injectable Suspension) in Patients With Prader-Willi Syndrome

NCT01613495 is registered in ClinicalTrials.gov with Oregon Health and Science University as lead sponsor.

NCT NCT01613495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01613495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ghrelin Suppression by Sandostatin LAR® Depot (Octreotide Acetate for Injectable Suspension) in Patients With Prader-Willi Syndrome
Lead sponsor
Oregon Health and Science University
Phase
Not applicable
Overall status
Unknown status
Start date
August 31, 2005
Completion date
November 30, 2024
Enrollment
2 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prader willis syndrome